Related Experiment Video
Updated: Oct 5, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
A Filippone1, M Lanza1, D Mannino1
1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, viale Ferdinando Stagno D'Alcontres, 31, 98166, Messina, Italy.
Abstract:
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell collapse. The binding of PD-1 to its ligand programmed death-ligand 1 (PD-L1) activates downstream signaling pathways and inhibits T cell activation in the perspective of immune system mechanism and regulation in tumor progression. It is well reported that tumors adopt certain immune-checkpoint pathways as a mechanism of resistance against immune cells such as T cells that are specific for tumor antigens. Indeed, the PD-1/PD-L1 pathway controls the induction and maintenance of immune tolerance within the tumor microenvironment. Thus, the PD-1/PD-L1 checkpoint regulation appears to be of extreme importance as well as the immunotherapy targeting that via and the using of PD-1/PD-L1 inhibitors that have changed the scenario of brain cancer treatment and survival. Here, we review the mechanism of action of PD-1 and PD-L1, the PD/PDL-1 signaling pathway involved in the progression of brain tumors, and its application as cancer immunotherapy counteracting tumor escape in central nervous system.
Insights
Programmed death-1 (PD-1) and its ligand PD-L1 regulate T cell activity, impacting tumor progression. Targeting this pathway with inhibitors offers a promising strategy for brain cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Neuroscience
Background:
- Programmed death-1 (PD-1) is a T cell receptor crucial for immune regulation.
- Tumors exploit the PD-1/PD-L1 pathway to evade immune responses.
- This pathway is vital for immune tolerance within the tumor microenvironment.
Purpose of the Study:
- To review the mechanism of action of PD-1 and PD-L1.
- To elucidate the PD-1/PD-L1 signaling pathway in brain tumor progression.
- To discuss the application of PD-1/PD-L1 inhibitors in central nervous system cancer immunotherapy.
Main Methods:
- Literature review on PD-1/PD-L1 pathway.
- Analysis of PD-1/PD-L1 signaling in brain tumors.
- Review of immunotherapy strategies targeting PD-1/PD-L1.
Main Results:
- PD-1/PD-L1 binding inhibits T cell activation and promotes tumor immune evasion.
- The PD-1/PD-L1 pathway is implicated in the development and maintenance of immune tolerance in brain tumors.
- PD-1/PD-L1 inhibitors have demonstrated efficacy in altering brain cancer treatment outcomes.
Conclusions:
- Understanding PD-1/PD-L1 signaling is critical for developing effective brain cancer therapies.
- Targeting the PD-1/PD-L1 checkpoint is a key immunotherapy strategy against central nervous system tumors.
- PD-1/PD-L1 inhibitors represent a significant advancement in brain cancer treatment and patient survival.
